Results 21 to 30 of about 249,854 (357)

Antiplatelet drugs [PDF]

British Journal of Haematology, 2008
SummaryPlatelets play a major role in thromboembolic diseases, and so antiplatelet therapy remains crucial in treatment and prophylaxis. Upon vascular injury, platelets rapidly adhere to the exposed subendothelial matrix, after which they become activated, resulting in the recruitment of additional platelets from the circulation to eventually form a ...
Simon F, De Meyer, Karen, Vanhoorelbeke, Katleen, Broos, Isabelle I, Salles, Hans, Deckmyn   +4 more
openaire   +2 more sources

Percutaneous coronary intervention with drug‐coated balloon‐only strategy combined with single antiplatelet treatment in patients at high bleeding risk: Single center experience of a novel concept

Catheterization and cardiovascular interventions, 2023
At least 1 month of dual antiplatelet therapy is required after coronary stenting. The aim of this all‐comers retrospective registry study was to assess the efficacy and safety of percutaneous coronary intervention (PCI) using drug‐coated balloon (DCB ...
Alma Räsänen, J. Kärkkäinen, Antti Eranti, Jaakko Eränen, T. Rissanen   +4 more
semanticscholar   +1 more source

Sclerobanding in the treatment of second and third degree hemorrhoidal disease in high risk patients on antiplatelet/anticoagulant therapy without suspension: a pilot study

Frontiers in Surgery, 2023
IntroductionAround 20% of population in western countries is under anticoagulant treatment. However, there is paucity of evidence about the treatment of HD in patients under anticoagulant/antiplatelet therapy, although both suspension and continuation in
Francesco Pata, Francesco Pata, Luigi M. Bracchitta, Bruno Nardo, Gaetano Gallo, Giancarlo D’Ambrosio, Salvatore Bracchitta   +6 more
doaj   +1 more source

Dual Antiplatelet Therapy: A Concise Review for Clinicians

Life, 2023
Dual antiplatelet therapy (DAPT) combines two antiplatelet agents to decrease the risk of thrombotic complications associated with atherosclerotic cardiovascular diseases. Emerging data about the duration of DAPT is being published continuously.
H. H. Virk, Johao Escobar, Mario Rodriguez, E. Bates, U. Khalid, H. Jneid, Y. Birnbaum, Glenn N. Levine, Sidney C. Smith, C. Krittanawong   +9 more
semanticscholar   +1 more source

Antiplatelet therapy after percutaneous coronary intervention.

EuroIntervention, 2022
Antiplatelet therapy is key to reducing local thrombotic complications and systemic ischaemic events among patients undergoing percutaneous coronary interventions (PCI), but it is inevitably associated with increased bleeding.
D. Angiolillo, M. Galli, J. Collet, A. Kastrati, M. O’Donoghue   +4 more
semanticscholar   +1 more source

Outcomes in Antiplatelet‐Associated Intracerebral Hemorrhage in the TICH‐2 Randomized Controlled Trial

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2021
Background Antiplatelet therapy increases the risk of hematoma expansion in intracerebral hemorrhage (ICH) while the effect on functional outcome is uncertain.
Z. Law, Michael Desborough, I. Roberts, R. Al‐Shahi Salman, T. England, D. Werring, Thompson G. Robinson, K. Krishnan, R. Dineen, A. Laska, N. Peters, J. Egea-Guerrero, M. Karliński, Hanne Christensen, Christine Roffe, Dániel Bereczki, Serefnur Ozturk, Jegan Thanabalan, R. Collins, M. Beridze, Philip M. Bath, N. Sprigg   +21 more
semanticscholar   +1 more source

Antiplatelet Use in Ischemic Stroke

The Annals of Pharmacotherapy, 2022
Objective: A literature review of antiplatelet agents for primary and secondary stroke prevention, including mechanism of action, cost, and reasons for lack of benefit.
Marharyta Kamarova, S. Baig, Hamish Patel, K. Monks, M. Wasay, Ali N Ali, J. Redgrave, A. Majid, S. Bell   +8 more
semanticscholar   +1 more source

Antiplatelet therapy in cardiovascular disease: Current status and future directions

British Journal of Clinical Pharmacology, 2022
Antiplatelet medications remain a cornerstone of therapy for atherosclerotic cardiovascular and cerebrovascular diseases. In primary prevention (patients with cardiovascular risk factors but no documented events, symptoms or angiographic disease), there ...
G. Passacquale, Pankaj Sharma, D. Perera, A. Ferro   +3 more
semanticscholar   +1 more source

9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xanthene-3-one is a potentially novel antiplatelet drug which antagonizes the effect of thromboxane A2 [PDF]

, 2018
Background: Currently, used oral antiplatelet drugs are both limited and associated with the risk of treatment failure/resistance. Research in this area is hence highly desired.
Applová, Lenka, Durić, Kemal, Karlíčková, Jana, Macáková, Kateřina, Mladĕnka, Přemysl, Muratović, Samija, Saso, Luciano, Veljović, Elma, Završnik, Davorka   +8 more
core   +1 more source

Antioxidant Properties of Oral Antithrombotic Therapies in Atherosclerotic Disease and Atrial Fibrillation

Antioxidants, 2023
The thrombosis-related diseases are one of the leading causes of illness and death in the general population, and despite significant improvements in long-term survival due to remarkable advances in pharmacologic therapy, they continue to pose a ...
Luigi Falco, Viviana Tessitore, Giovanni Ciccarelli, Marco Malvezzi, Antonello D’Andrea, Egidio Imbalzano, Paolo Golino, Vincenzo Russo   +7 more
doaj   +1 more source